Charles River Laboratoire France Crlf086650041

How does a therapy go from being a patient’s dream to reality? The drug development process is long, tedious and complex. We’ve broken it down into four simple steps to help you understand how a drug goes from just an idea to the shelves of your pharmacy. #everystepoftheway https://bit.ly/2KIeDFd For additional languages: Dutch – https://youtu.be/t6F3jWeotg4 French EU – https://youtu.be/jeA_HabIavc French CA – https://youtu.be/Yy09cmNGTnA German – https://youtu.be/kRlpeMhU4Y8 Italian – https://youtu.be/G6n5879hKPU Mandarin – https://youtu.be/8jlLt8YyCI4 Japanese – https://youtu.be/kpyJIf4zx-k

Behind every patient stands thousands of scientists and researchers working together to develop life-saving drugs. Watch Evie’s Story. #EveryPatient http://bit.ly/2EYTuXz

At Charles River, our purpose is clear and our passion is strong: Together We Create Healthier Lives. Our values: Care, Lead, Own and Collaborate should guide our decisions and actions, they are the standards we hold ourselves to each and every day.

http://bit.ly/2BabGcv Drug development can take more than 10 years. Meet the Boston Children’s Hospital and Charles River team behind a tailormade therapy that was developed in a fraction of that time, for a single patient. Watch Mila’s story. #EveryLife Learn more: »Eureka: https://bit.ly/35t23Dw »C&EN: https://bit.ly/2MkKcaq »Vital Science Podcast: http://bit.ly/2oUCtXZ . . . At Charles River, we are passionate about our role in improving the quality of people’s lives. Our mission, our excellent science and our strong sense of purpose guides us in all that we do, and we approach each day with the knowledge that our work helps to improve the health and well-being of many across the globe. To learn more, please visit: » Our website, criver.com » Eureka, our scientific blog, eureka.criver.com » Sounds of Science, our monthly podcast, eureka.criver.com/podcast » Vital Science, our monthly podcast, criver.com/vitalsciencepodcast » Bonus! You can subscribe to Sounds of Science and Vital Science on Apple Podcasts, Spotify or wherever else you get your podcasts. » Facebook, facebook.com/charlesriverlabs » LinkedIn, linkedin.com/company/charles-river-laboratories » Twitter, twitter.com/criverlabs » Instagram, @criverlabs

What would you do if you learned you’d inherited a fatal genetic mutation for Prion disease? Follow lawyer-turned-researcher Sonia Vallabh and her husband Eric Minikel on their race against time. #raceagainsttime #everydaycounts #CRLWorldCon

The video (shown below) shows zebrafish development from a single cell through about 22 hours post fertilization.

Cancer Researchers, reveal your compound’s immunoreactivity in real-time.

Our team discusses the methodology and benefits of using microdialysis. Want to learn more about our microdialysis services? http://bit.ly/2OOYnU5

See how our partnership with Rutgers University is providing horseshoe crabs a jump-start on life.

A look at microdialysis and bioanalysis in CNS research.

https://bit.ly/2AE8DJh Jack O’Brien Burke was born to Jake Burke and Elizabeth O’Brien in 2005. At age two, while the couple was expecting the birth of their second son Luke, they received a devastating diagnosis: Jack had neurofibromatosis (NF). . . . At Charles River, we are passionate about our role in improving the quality of people’s lives. Our mission, our excellent science and our strong sense of purpose guides us in all that we do, and we approach each day with the knowledge that our work helps to improve the health and well-being of many across the globe. To learn more, please visit: » Our website, criver.com » Eureka, our scientific blog, eureka.criver.com » Sounds of Science, our monthly podcast, eureka.criver.com/podcast » Vital Science, our monthly podcast, criver.com/vitalsciencepodcast » Bonus! You can subscribe to Sounds of Science and Vital Science on Apple Podcasts, Spotify or wherever else you get your podcasts. » Facebook, facebook.com/charlesriverlabs » LinkedIn, linkedin.com/company/charles-river-laboratories » Twitter, twitter.com/criverlabs » Instagram, @criverlabs

For Logan, a Charles River scientist, Huntington’s disease research is focused around a repeating CAG gene. For Jenne, a young mother of two, Huntington’s disease research is hope. When Jenne discovered she carries the HD gene and only has a few years before she starts presenting symptoms, her world was turned upside down. Now she’s waiting while scientists at Charles River and CHDI Foundation race to find an effective treatment.

The Celsis Advance II is a rapid microbial detection instrument that falls in seamlessly with your current test routines for both direct inoculation and membrane filtration testing methods. For samples that are non-filterable, opaque, pigmented, or viscous, Celsis® systems are an ideal test method to screen samples for contamination in as little as 18-24 hours. To learn more about Celsis® rapid microbial detection from Charles River, visit criver.com/celsis.

Eureka’s Live discussion at AACR 2018

High-throughput monoclonal antibody library screening has never been faster. Glimpse the future: www.criver.com/antibody

Originally aired in June 2019 on De Barometer (RLT-Z). Our discovery-focused site in Leiden uses a combination of functional genomics technologies coupled with screening in human (primary) cells to identify and validate critical proteins in disease pathways. Learn more: http://bit.ly/2ZBVlYa.

This video demonstrates the simplicity of using the Celsis Advance II™ in conjunction bioburden testing via membrane filtration. When samples are filterable and require enumeration, Celsis® rapid detection is extremely useful to obtain the fastest time result (18-24 hours) when 0 CFU is typically expected, such as for water for injection (WFI) and bulk drug substance. To learn more about Celsis® rapid microbial detection from Charles River, visit criver.com/celsis

A novel collaboration forged by the California Institute of Regeneration Medicine is helping stem cell scientists translate their therapies from the bench to the clinic.

Our panel of experts discuss hot topics in oncology from AACR 2018.

What would you say to the people who saved your life? Go behind the scenes with Evie and her family as they talk to the researchers who saved her life. #EveryPatient http://bit.ly/2EYTuXz

http://bit.ly/2V2NRfJ Every year, 38,000 Scoliosis patients undergo spinal fusion surgery. If left untreated, moderate to severe cases can lead to pain and increasing deformity, as well as potential heart and lung damage. Treating this condition relies on a number of medical devices, drugs, and therapies, which all need to be delivered timely, effectively, and most importantly, safely. Meet Niva, an 11-year old scoliosis patient who relies on sound quality control from the medical and pharmaceutical industries for her ongoing treatment. Watch the short video to uncover how her journey is impacted by your work.

Discovery from Charles River is the partner of choice with a proven track record of successful drug development. Offering scientific excellence and integrated services that take clients from hit ID to IND, our client-focused collaborative team works with clients to find and follow the optimum path to market. Find out more: http://bit.ly/2JqkHRR

Scientists from Charles River and Michael J. Fox Foundation discuss the preclinical picture.

Charles River is developing translational in vitro assay to steer your drug discovery through to clinic.

Are you faced with too many options on the drug discovery path? Knowing which step to take can be challenging. Collaborations with scientists at CR have a vested interest in the outcome of your project. Consulting with our scientists is two way street to solving problems and as such long term relationships are built and we share your passion for the work.

It’s impossible to anticipate the challenges you’ll face on the journey to market. Your best asset is a nimble, versatile nonclinical partner who knows how to scale scientific hurdles, overcome regulatory snags, and clear a path to approval.

Panel discussion from AACR 2018.

Explore our cell and gene therapy R&D solutions: http://bit.ly/2mCPdxD

On November 11, 2019, Jim Foster, Chairman, President & CEO of Charles River joined Jim Cramer on Mad Money to discuss the biotech industry, growth in China, and the future of Charles River. According to Jim: “Our business is not linear. We talk about that all the time. People don’t start studies and stop studies congruent with our fiscal quarters, but we’re really thrilled with our long-term growth rates..." Additionally, we recently reported our third quarter results. In Q3 2019, revenue was 668.0 million, an increase of 14.1% from 585.3 million in Q3 2018. Learn more here: https://bit.ly/2JWc1o2

Our fully-integrated, multidisciplinary Field Trials team have been clearing hurdles and paving the way to successful agrochemical registration for twenty years.

Come together September 23-24, as we explore novel approaches to drug development that effectively reduce program timelines and accelerate delivery to the clinic. #CRLWorldCon Learn more: http://bit.ly/2KsIrIF

Charles River’s translational platform for immuno-oncology supports the collection of rich data to inform better decision making, moving you effectively from target discovery and validation through to humanized mouse models and on to the clinic. http://bit.ly/2yagL2w

Drug development can take more than 10 years. Meet the Boston Children’s Hospital and Charles River team behind a tailormade therapy that was developed in a fraction of that time, for a single patient. Watch Mila’s story. #EveryLife . . . At Charles River, we are passionate about our role in improving the quality of people’s lives. Our mission, our excellent science and our strong sense of purpose guides us in all that we do, and we approach each day with the knowledge that our work helps to improve the health and well-being of many across the globe. To learn more, please visit: » Our website, criver.com » Eureka, our scientific blog, eureka.criver.com » Sounds of Science, our monthly podcast, eureka.criver.com/podcast » Vital Science, our monthly podcast, criver.com/vitalsciencepodcast » Bonus! You can subscribe to Sounds of Science and Vital Science on Apple Podcasts, Spotify or wherever else you get your podcasts. » Facebook, facebook.com/charlesriverlabs » LinkedIn, linkedin.com/company/charles-river-laboratories » Twitter, twitter.com/criverlabs » Instagram, @criverlabs

Join us September 10–12 for our 24th Annual Biotech Symposium, a three-day event that unites drug development professionals in an interactive setting to discuss the nonclinical development of biotherapeutics in La Jolla, CA. http://bit.ly/2In6pAi

In 2015 Dr. Berent became the Chief Science Officer for the Foundation for Angelman Syndrome Therapeutics and has been integral in driving the research portfolio in novel treatment options for this rare genetic disorder. In 2017 Dr. Berent became the Chielf Operating Officer of GeneTx Biotherapeutics, a company with a sole mission to advance antisense oligonucleotide therapies toward human clinical trials for the treatment of Angelman syndrome. Congratulations to her and the GenetX team on their partnership with Ultragenyx. Hear Allyson talk about the personal journey of drug development at #CRLWorldCon. Register today! http://bit.ly/2L6zaVZ

Many biotech industry leaders are finding themselves in uncharted waters: the science is more sophisticated than ever, producing paradigm-altering treatments. But, historically high R&D costs and low success rates have emphasized the need to identify drugs focused on translationally-relevant targets in the most cost and time efficient way. How do you thrive in this new era, and where do CROs fit into the picture? John Montana, PhD, Corporate Vice President, Integrated Drug Development and Strategic Projects, Charles River explains how an integrated approach adds value to drug discovery programs. Learn more here: https://bit.ly/2EGYHAo

We should all be proud of our accomplishments this year, which can be reviewed in the video below. Thank you for everything you do, every day to help us fulfill our purpose: Together, we create healthier lives. I am grateful to be part of this impressive Charles River team. I look forward to building on our momentum in 2020. Interested in a career at Charles River? Apply online: https://jobs.criver.com/

Don’t just throw it over the fence build relationships with scientists who have been on your side of the bench. Learn more: http://bit.ly/2L7Ir1w

How two parents put a face on Rare Disease. A discussion from our 2nd Annual World Congress.

Challenges in using gene therapy to treat rare diseases. A discussion from our 2nd Annual World Congress.

Finding the right combination of resources to meet the needs of a complex drug discovery project can be challenging, especially having your team smoothly interface with a variety of external partners. How do you keep up with all of the projects being run at various CROs?

As a virtual biotech, you’re in a challenging situation. You need a streamlined process and a diverse group of experts to help your skeleton crew reach the exit point.

A recap of our successful 2017 event and what’s to come in 2018!

Functional protein isolation by Capture Coumpound Mass Spectrometry (CCMS)

Dare to change the way you think about your program. We invite you to visit booth #2519 at Society for Neuroscience Annual Meeting to explore how Charles River can partner with you to solve current problems in your neuroscience drug discovery programs. For more information: http://bit.ly/2CSSsKA

Learn more about our IDD Team: http://bit.ly/2A0zcXz

Join us September 9-11 for our 25th Annual Biotech Symposium, a three-day event that unites drug development professionals in an interactive setting to discuss the nonclinical development of biotherapeutics in Carlsbad, CA. Register today! http://bit.ly/2ZaSIwL

Our facility in South San Francisco offers sophisticated in vivo efficacy and pharmacokinetics testing to better understand neuroscience disease pathophysiology, and is a center of excellence for microdialysis and EEG testing.

Behind every patient stands thousands of scientists and researchers, all working together to develop life-saving drugs. As you may have seen, many employees were involved in developing personalized medicine for Mila, just over a year from her diagnosis. This amazing achievement, racing through the holidays to get Mila her drug, showcases the dedication of our employees. http://bit.ly/2BabGcv #EveryLife

Joe Cornicelli, PhD, Sr Director, in vivo Pharmacology, describes the challenges and opportunities for researchers pursuing new treatments for non-alcoholic steatohepatitis (NASH)